Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Comprar returned no results
Showing 46 to 60 of 556 results for compare

  1. Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)

    Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Last updated
    3 July 2024
    View recommendations

    Sections for TA688

  2. NICE encourages further research on endovascular aneurysm sealing for abdominal aortic aneurysmthis procedure in the form of controlled clinical trials, observational studies and analysis of registry data. Details about patient selection, including anatomical details, should be clearly documented.Research should compare the procedure with conventional stent graft endovascular aneurysm repair. All complications should be reported. Long-term outcomes should be described as data become available. NICE may update the guidance on publication of further evidence.

    including anatomical details, should be clearly documented.Research should compare the procedure with conventional stent graft...

    Research recommendation
    Published
    21 March 2016

  3. Selective peripheral denervation for cervical dystonia (HTG51)

    Evidence-based recommendations on selective peripheral denervation for cervical dystonia. This involves cutting the nerves to the muscles of the neck through a large skin incision.

    HealthTech guidance
    Published
    25 August 2004
    View recommendations

    Sections for HTG51

  4. Identification and monitoring:- What are the demographic characteristics and rates of progression to type 2 diabetes among people with a high risk score but normal blood glucose levels (fasting plasma glucose of less than 5.5 mmol/l or HbA1c of less than 42 mmol/mol)? How does this compare with people who have both a high risk score and blood glucose levels that indicate impaired glucose regulation (fasting plasma glucose 5.5–6.9 mmol/l or HbA1c 42–47 mmol/mol (6.0–6.4%)?

    less than 5.5 mmol/l or HbA1c of less than 42 mmol/mol)? How does this compare with people who have both a high risk score and blood...

    Research recommendation
    Published
    9 June 2015

  5. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer . Patient decision aid on intrabeam radiotherapy for treating early breast cancer

    How do the benefits and drawbacks of external radiotherapy and Intrabeam compare? There is a large amount of evidence for external...

  6. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1030)

    Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    15 January 2025

    Sections for TA1030

  7. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

    Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.

    Technology appraisal guidance
    Published
    13 April 2022
    View recommendations

    Sections for TA783

  8. Few women use contraception perfectly (that is, exactly in accordance with the product instructions) and consistently. Pregnancy rates during typical use reflect effectiveness of a method among women who use the method incorrectly or inconsistently. Few data are available on typical use of any contraceptive method among women in the UK. Much of the data on contraceptive effectiveness used in the guideline come from clinical trials or surveys undertaken in other countries such as the USA. Large prospective cohort studies are needed to compare the contraceptive effectiveness of LARC methods with non‑LARC methods during typical use in the UK.

    countries such as the USA. Large prospective cohort studies are needed to compare the contraceptive effectiveness of LARC methods with...

    Research recommendation
    Published
    25 October 2019

  9. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA173

  10. Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment.

    Technology appraisal guidance
    Published
    16 December 2020
    View recommendations

    Sections for TA666

  11. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

    Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA643

  12. Transcutaneous electrical neuromuscular stimulation for urinary incontinence (HTG636)

    Evidence-based recommendations on transcutaneous electrical neuromuscular stimulation for urinary incontinence in adults. This involves stimulating nerves and muscles in the pelvic floor to strengthen the muscles and reduce urine leaks.

    HealthTech guidance
    Published
    24 August 2022
    View recommendations

    Sections for HTG636

  13. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417

  14. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for vaginal vault prolapse

    type of treatment: what it involves, the risks and benefits, and how they compare to each other. If the type of surgery you would prefer...

  15. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

    Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    10 April 2024
    View recommendations

    Sections for TA964